Drug-induced oxidative stress and toxicity

Journal of Toxicology

Volumn 2012, Issue , 2012, Pages

  Deavall, Damian G ^a   Martin, Elizabeth A ^a   Horner, Judith M ^a   Roberts, Ruth ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; AMIFOSTINE; ASCORBIC ACID; CARNITINE; CARVEDILOL; CHLORPROMAZINE; CISPLATIN; DICLOFENAC; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; PARACETAMOL; PITAVASTATIN; PROPOFOL; RAZOXANE; REACTIVE OXYGEN METABOLITE; TRASTUZUMAB; UBIDECARENONE; ZIDOVUDINE;

ANTIOXIDANT ACTIVITY; ANTIVIRAL THERAPY; APOPTOSIS; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELLULAR STRESS RESPONSE; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM CANCER; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOXICITY; ENZYME REGULATION; HEART DISEASE; HEART FAILURE; HEART INJURY; HEART MITOCHONDRION; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; HYPOTENSION; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; LIVER TOXICITY; LUNG CANCER; MYOPATHY; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OVARY CANCER; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PERSONALIZED MEDICINE; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; TACHYCARDIA; TARGET CELL; TESTIS CANCER;

EID: 84866173741     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2012/645460     Document Type: Review

References (117)

1. Devasagayam T. P. A., Tilak J. C., Boloor K. K., Sane K. S., Ghaskadbi S. S., Lele R. D., Free radicals and antioxidants in human health: current status and future prospects. Journal of Association of Physicians of India 2004 52 794 804 2-s2.0-19444387198 (Pubitemid 41279997)
2. Guzik T. J., West N. E. J., Pillai R., Taggart D. P., Channon K. M., Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002 39 6 1088 1094 2-s2.0-0036285223 10.1161/01.HYP.0000018041.48432.B5 (Pubitemid 34620129)
3. Harrison J. F., Hollensworth S. B., Spitz D. R., Copeland W. C., Wilson G. L., LeDoux S. P., Oxidative stress-induced apoptosis in neurons correlates with mitochondrial DNA base excision repair pathway imbalance. Nucleic Acids Research 2005 33 14 4660 4671 2-s2.0-23844439393 10.1093/nar/gki759 (Pubitemid 41222580)
4. Maynard S., Schurman S. H., Harboe C., de Souza-Pinto N. C., Bohr V. A., Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009 30 1 2 10 2-s2.0-58949084649 10.1093/carcin/bgn250
5. Waris G., Ahsan H., Reactive oxygen species: role in the development of cancer and various chronic conditions. Journal of Carcinogenesis 2006 5, article 14 2-s2.0-33745265207 10.1186/1477-3163-5-14
6. Nobre H. V. Jr., Fonteles M. M. D. F., De Freitas R. M. D., Acute seizure activity promotes lipid peroxidation, increased nitrite levels and adaptive pathways against oxidative stress in the frontal cortex and striatum. Oxidative Medicine and Cellular Longevity 2009 2 3 130 137 2-s2.0-77953456203
7. Fraga C. G., Shigenaga M. K., Park J. W., Degan P., Ames B. N., Oxidative damage to DNA during aging: 8-Hydroxy-2'-deoxyguanosine in rat organ DNA and urine. Proceedings of the National Academy of Sciences of the United States of America 1990 87 12 4533 4537 2-s2.0-0025373259 10.1073/pnas.87.12.4533 (Pubitemid 20204136)
8. Neeley W. L., Essigmann J. M., Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products. Chemical Research in Toxicology 2006 19 4 491 505 2-s2.0-33646080824 10.1021/tx0600043
9. Spassky A., Angelov D., Influence of the local helical conformation on the guanine modifications generated from one-electron DNA oxidation. Biochemistry 1997 36 22 6571 6576 2-s2.0-0030965894 10.1021/bi962761d (Pubitemid 27242314)
10. Evans M. D., Dizdaroglu M., Cooke M. S., Oxidative DNA damage and disease: induction, repair and significance. Mutation Research 2004 567 1 1 61 2-s2.0-4444339833 10.1016/j.mrrev.2003.11.001 (Pubitemid 39162992)
11. Shibutani S., Takeshita M., Grollman A. P., Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature 1991 349 6308 431 434 2-s2.0-0025981359 10.1038/349431a0 (Pubitemid 21926107)
12. Kryston T. B., Georgiev A. B., Pissis P., Georgakilas A. G., Role of oxidative stress and DNA damage in human carcinogenesis. Mutation Research 2011 711 1-2 193 201 2-s2.0-79956191022 10.1016/j.mrfmmm.2010.12.016
13. Einolf H. J., Schnetz-Boutaud N., Guengerich F. P., Steady-state and pre-steady-state kinetic analysis of 8-oxo-7,8- dihydroguanosine triphosphate incorporation and extension by replicative and repair DNA polymerases. Biochemistry 1998 37 38 13300 13312 2-s2.0-0032558424 10.1021/bi981346d (Pubitemid 28449575)
14. Cooke M. S., Evans M. D., Dizdaroglu M., Lunec J., Oxidative DNA damage: mechanisms, mutation, and disease. The FASEB Journal 2003 17 10 1195 1214 2-s2.0-0038799736 10.1096/fj.02-0752rev (Pubitemid 36775767)
15. Purmal A. A., Kow Y. W., Wallace S. S., Major oxidative products of cytosine, 5-hydroxycytosine and 5-hydroxyuracil, exhibit sequence context-dependent mispairing in vitro. Nucleic Acids Research 1994 22 1 72 78 2-s2.0-0028341311 (Pubitemid 24157436)
16. Himmelstein M. W., Boogaard P. J., Cadet J., Farmer P. B., Kim J. H., Martin E. A., Persaud R., Shuker D. E. G., Creating context for the use of DNA adduct data in cancer risk assessment: II. Overview of methods of identification and quantitation of DNA damage Analysis of DNA damage. Critical Reviews in Toxicology 2009 39 8 679 694 2-s2.0-70350518538 10.1080/10408440903164163
17. D'Errico M., Parlanti E., Dogliotti E., Mechanism of oxidative DNA damage repair and relevance to human pathology. Mutation Research 2008 659 1-2 4 14 2-s2.0-47849100494 10.1016/j.mrrev.2007.10.003
18. Karakaya A., Jaruga P., Bohr V. A., Grollman A. P., Dizdaroglu M., Kinetics of excision of purine lesions from DNA by Escherichia coli Fpg protein. Nucleic Acids Research 1997 25 3 474 479 2-s2.0-0030818650 10.1093/nar/25.3.474 (Pubitemid 27298226)
19. Dizdaroglu M., Substrate specificities and excision kinetics of DNA glycosylases involved in base-excision repair of oxidative DNA damage. Mutation Research 2003 531 1-2 109 126 2-s2.0-0345448169 10.1016/j.mrfmmm.2003.07.003 (Pubitemid 37456726)
20. Dizdaroglu M., Base-excision repair of oxidative DNA damage by DNA glycosylases. Mutation Research 2005 591 1-2 45 59 2-s2.0-27844495699 10.1016/j.mrfmmm.2005.01.033 (Pubitemid 41654839)
21. Collins A. R., Duthie S. J., Dobson V. L., Direct enzymic detection of endogenous oxidative base damage in human lymphocyte DNA. Carcinogenesis 1993 14 9 1733 1735 2-s2.0-0027375157 (Pubitemid 23290881)
22. Wallace S. S., Biological consequences of free radical-damaged DNA bases. Free Radical Biology and Medicine 2002 33 1 1 14 2-s2.0-0036628726 10.1016/S0891-5849(02)00827-4 (Pubitemid 34681001)
23. Yu S. L., Lee S. K., Johnson R. E., Prakash L., Prakash S., The stalling of transcription at abasic sites is highly mutagenic. Molecular and Cellular Biology 2003 23 1 382 388 2-s2.0-0037215540 10.1128/MCB.23.1.382-388.2003 (Pubitemid 36008528)
24. Achanta G., Huang P., Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Research 2004 64 17 6233 6239 2-s2.0-4344577088 10.1158/0008-5472.CAN-04-0494 (Pubitemid 39129425)
25. Dalle-Donne I., Rossi R., Colombo R., Giustarini D., Milzani A., Biomarkers of oxidative damage in human disease. Clinical Chemistry 2006 52 4 601 623 2-s2.0-33645459044 10.1373/clinchem.2005.061408
26. Stone K., Ksebati M. B., Marnett L. J., Investigation of the adducts formed by reaction of malondialdehyde with adenosine. Chemical Research in Toxicology 1990 3 1 33 38 2-s2.0-0025240126 (Pubitemid 20128626)
27. Niedernhofer L. J., Daniels J. S., Rouzer C. A., Greene R. E., Marnett L. J., Malondialdehyde, a product of lipid peroxidation, is mutagenic in human cells. The Journal of Biological Chemistry 2003 278 33 31426 31433 2-s2.0-0041731614 10.1074/jbc.M212549200 (Pubitemid 36994664)
28. Avery S. V., Molecular targets of oxidative stress. Biochemical Journal 2011 434 2 201 210 2-s2.0-79951518607 10.1042/BJ20101695
29. Gago-Dominguez M., Jiang X., Castelao J. E., Lipid peroxidation, oxidative stress genes and dietary factors in breast cancer protection: a hypothesis. Breast Cancer Research 2007 9 1, article 201 2-s2.0-34248165632
30. Davì G., Falco A., Patrono C., Lipid peroxidation in diabetes mellitus. Antioxidants and Redox Signaling 2005 7 1-2 256 268 2-s2.0-13244258258 10.1089/ars.2005.7.256 (Pubitemid 40187942)
31. Till G. O., Hatherill J. R., Tourtellotte W. W., Lipid peroxidation and acute lung injury after thermal trauma to skin. Evidence of a role for hydroxyl radical. American Journal of Pathology 1985 119 3 376 384 2-s2.0-0021833156 (Pubitemid 15051886)
32. Montine T. J., Neely M. D., Quinn J. F., Beal M. F., Markesbery W. R., Roberts L. J., Morrow J. D., Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biology and Medicine 2002 33 5 620 626 2-s2.0-0036710931 10.1016/S0891-5849(02)00807-9 (Pubitemid 35245834)
33. Pall H. S., Williams A. C., Blake D. R., Lipid peroxidation and Parkinson's disease. The Lancet 1986 2 8511 870 871 2-s2.0-0022978476 (Pubitemid 17178075)
34. Stocker R., Keaney J. F., Role of oxidative modifications in atherosclerosis. Physiological Reviews 2004 84 4 1381 1478 2-s2.0-4644310560 10.1152/physrev.00047.2003 (Pubitemid 39302636)
35. Östman A., Frijhoff J., Sandin Å., Böhmer F.-D., Regulation of protein tyrosine phosphatases by reversible oxidation. Journal of Biochemistry 2011 150 4 345 356 2-s2.0-80053513183 10.1093/jb/mvr104
36. Diao Y., Liu W., Wong C. C. L., Wang X., Lee K., Cheung P. Y., Pan L., Xu T., Han J., Yates J. R., Zhang M., Wu Z., Oxidation-induced intramolecular disulfide bond inactivates mitogen-activated protein kinase kinase 6 by inhibiting ATP binding. Proceedings of the National Academy of Sciences of the United States of America 2010 107 49 20974 20979 2-s2.0-78650476731 10.1073/pnas.1007225107
37. Bandyopadhyay S., Gronostajski R. M., Identification of a conserved oxidation-sensitive cysteine residue in the NFI family of DNA-binding proteins. The Journal of Biological Chemistry 1994 269 47 29949 29955 2-s2.0-0028139041 (Pubitemid 24365164)
38. Medicherla B., Goldberg A. L., Heat shock and oxygen radicals stimulate ubiquitin-dependent degradation mainly of newly synthesized proteins. Journal of Cell Biology 2008 182 4 663 673 2-s2.0-50249175909 10.1083/jcb.200803022
39. Schmalhausen E. V., Pleten' A. P., Muronetz V. I., Ascorbate-induced oxidation of glyceraldehyde-3-phosphate dehydrogenase. Biochemical and Biophysical Research Communications 2003 308 3 492 496 2-s2.0-0042666797 10.1016/S0006-291X(03)01421-9 (Pubitemid 36945519)
40. Vives Corrons J. L., Pujades M. A., Colomer D., Increase of enzyme activities following the in vitro peroxidation of normal human red blood cells. Enzyme 1988 39 1 1 7 2-s2.0-0023852405 (Pubitemid 18038661)
41. Kodiha M., Vol. 2012, pp. 1-18, 2012, Stochaj U., Nuclear transport: a switch for the oxidative stresssignaling circuit? Journal of Signal Transduction 2012 2012 18 208650 10.1155/2012/208650
42. Tretter L., Adam-Vizi V., Inhibition of krebs cycle enzymes by hydrogen peroxide: a key role of α -ketoglutarate dehydrogenase in limiting NADH production under oxidative stress. Journal of Neuroscience 2000 20 24 8972 8979 2-s2.0-0034671429 (Pubitemid 32042897)
43. Cecarini V., Gee J., Fioretti E., Amici M., Angeletti M., Eleuteri A. M., Keller J. N., Protein oxidation and cellular homeostasis: emphasis on metabolism. Biochimica et Biophysica Acta 2007 1773 2 93 104 2-s2.0-33846268796 10.1016/j.bbamcr.2006.08.039 (Pubitemid 46123609)
44. Stadtman E. R., Levine R. L., Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003 25 3-4 207 218 2-s2.0-0346100345 10.1007/s00726-003-0011-2 (Pubitemid 38043943)
45. Berlett B. S., Stadtman E. R., Protein oxidation in aging, disease, and oxidative stress. The Journal of Biological Chemistry 1997 272 33 20313 20316 2-s2.0-0030841350 10.1074/jbc.272.33.20313 (Pubitemid 27355575)
46. Shringarpure R., Grune T., Mehlhase J., Davies K. J. A., Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. The Journal of Biological Chemistry 2003 278 1 311 318 2-s2.0-0037414834 10.1074/jbc.M206279200 (Pubitemid 36043578)
47. Shacter E., Protein oxidative damage. Methods in Enzymology 2000 319 428 436 2-s2.0-0033938817 (Pubitemid 30448062)
48. Ryter S. W., Hong P. K., Hoetzel A., Park J. W., Nakahira K., Wang X., Choi A. M. K., Mechanisms of cell death in oxidative stress. Antioxidants and Redox Signaling 2007 9 1 49 89 2-s2.0-33845395850 10.1089/ars.2007.9.49 (Pubitemid 44901874)
49. Hatai T., Matsuzawa A., Inoshita S., Mochida Y., Kuroda T., Sakamaki K., Kuida K., Yonehara S., Ichijo H., Takeda K., Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria- dependent caspase activation. The Journal of Biological Chemistry 2000 275 34 26576 26581 2-s2.0-0034714355 10.1074/jbc.M003412200
50. Ichijo H., Nishida E., Irie K., Ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y., Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997 275 5296 90 94 2-s2.0-14444281569 10.1126/science.275.5296.90 (Pubitemid 27020316)
51. Dhanasekaran D. N., Reddy E. P., JNK signaling in apoptosis. Oncogene 2008 27 48 6245 6251 2-s2.0-54249119561 10.1038/onc.2008.301
52. Datta S. R., Brunet A., Greenberg M. E., Cellular survival: a play in three akts. Genes and Development 1999 13 22 2905 2927 2-s2.0-0032752063 10.1101/gad.13.22.2905
53. Hers I., Vincent E. E., Tavaré J. M., Akt signalling in health and disease. Cellular Signalling 2011 23 10 1515 1527 2-s2.0-79960716001 10.1016/j.cellsig.2011.05.004
54. Datta S. R., Dudek H., Xu T., Masters S., Haian F., Gotoh Y., Greenberg M. E., Akt phosphorylation of BAD couples survival signals to the cell- intrinsic death machinery. Cell 1997 91 2 231 241 2-s2.0-0030702123 10.1016/S0092-8674(00)80405-5 (Pubitemid 27456390)
55. Wang Y., Zeigler M. M., Lam G. K., Hunter M. C., Eubank T. D., Khramtsov V. V., Tridandapani S., Sen C. K., Marsh C. B., The role of the NADPH oxidase complex, p38 MARK, and Akt in regulating human monocyte/macrophage survival. American Journal of Respiratory Cell and Molecular Biology 2007 36 1 68 77 2-s2.0-33846075802 10.1165/rcmb.2006-0165OC (Pubitemid 46067709)
56. Brunet A., Datta S. R., Greenberg M. E., Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Current Opinion in Neurobiology 2001 11 3 297 305 2-s2.0-0035369623 10.1016/S0959-4388(00)00211-7 (Pubitemid 32524094)
57. Zhang R., Chae S., Lee J. H., Hyun J. W., The cytoprotective effect of butin against oxidative stress is mediated by the up-regulation of manganese superoxide dismutase expression through a PI3K/Akt/Nrf2-dependent pathway. Journal of Cellular Biochemistry 2012 113 6 1987 1997 2-s2.0-84859624232 10.1002/jcb.24068
58. Moore D. E., Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Safety 2002 25 5 345 372 2-s2.0-0036279441 (Pubitemid 34634272)
59. Gewirtz D. A., A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology 1999 57 7 727 741 2-s2.0-0033006172 10.1016/S0006-2952(98)00307-4 (Pubitemid 29094544)
60. Fortune J. M., Osheroff N., Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology 2000 64 221 253 2-s2.0-0033628701
61. Steinherz L. J., Steinherz P. G., Tan C. T. C., Heller G., Murphy M. L., Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991 266 12 1672 1677 2-s2.0-0025850827 10.1001/jama.266.12.1672
62. Šimůnek T., Štěrba M., Popelová O., Adamcová M., Hrdina R., Gerši V., Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacological Reports 2009 61 1 154 171 2-s2.0-66949171305
63. Menna P., Recalcati S., Cairo G., Minotti G., An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovascular Toxicology 2007 7 2 80 85 2-s2.0-34548301536 10.1007/s12012-007-0011-7 (Pubitemid 47339872)
64. Davies K. J. A., Doroshow J. H., Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. The Journal of Biological Chemistry 1986 261 7 3060 3067 2-s2.0-0022967083 (Pubitemid 17204909)
65. Doroshow J. H., Davies K. J. A., Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. The Journal of Biological Chemistry 1986 261 7 3068 3074 2-s2.0-0023028913 (Pubitemid 17204910)
66. Yoshida M., Shiojima I., Ikeda H., Komuro I., Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. Journal of Molecular and Cellular Cardiology 2009 47 5 698 705 2-s2.0-70349734337 10.1016/j.yjmcc.2009.07.024
67. Goormaghtigh E., Chatelain P., Caspers J., Ruysschaert J. M., Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochimica et Biophysica Acta 1980 597 1 1 14 2-s2.0-0019221914 (Pubitemid 10120606)
68. Pereira G. C., Silva A. M., Diogo C. V., Carvalho F. S., Monteiro P., Oliveira P. J., Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Current Pharmaceutical Design 2011 17 20 2113 2129 2-s2.0-80052226370 10.2174/138161211796904812
69. Nithipongvanitch R., Ittarat W., Cole M. P., Tangpong J., Clair D. K. S., Oberley T. D., Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)? Antioxidants and Redox Signaling 2007 9 7 1001 1008 2-s2.0-34250375254 10.1089/ars.2007.1632 (Pubitemid 46919601)
70. Wallace K. B., Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovascular Toxicology 2007 7 2 101 107 2-s2.0-34548299678 10.1007/s12012-007-0008-2 (Pubitemid 47339855)
71. Zhang Y. W., Shi J., Li Y. J., Wei L., Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Archivum Immunologiae et Therapiae Experimentalis 2009 57 6 435 445 2-s2.0-70450260555 10.1007/s00005-009-0051-8
72. Childs A. C., Phaneuf S. L., Dirks A. J., Phillips T., Leeuwenburgh C., Doxorubicin treatment in vivo causes cytochrome c release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Research 2002 62 16 4592 4598 2-s2.0-0037102148
73. Di Cosimo S., Heart to heart with trastuzumab: a review on cardiac toxicity. Targeted Oncology 2011 6 4 189 195 2-s2.0-84856049297 10.1007/s11523-011-0203-8
74. Zeglinski M., Ludke A., Jassal D. S., Singal P. K., Trastuzumab-induced cardiac dysfunction: a 'dual-hit' Experimental and Clinical Cardiology 2011 16 3 70 74 2-s2.0-80054886881
75. De Azambuja E., Bedard P. L., Suter T., Piccart-Gebhart M., Cardiac toxicity with anti-HER-2 therapies-what have we learned so far? Targeted Oncology 2009 4 2 77 88 2-s2.0-67349248085 10.1007/s11523-009-0112-2
76. Matsui H., Morishima I., Numaguchi Y., Toki Y., Okumura K., Hayakawa T., Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. Life Sciences 1999 65 12 1265 1274 2-s2.0-0033551890 10.1016/S0024- 3205(99)00362-8 (Pubitemid 29425963)
77. Doroshow J. H., Locker G. Y., Ifrim I., Myers C. E., Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. The Journal of Clinical Investigation 1981 68 4 1053 1064 2-s2.0-0019414005 (Pubitemid 11023534)
78. Lai H. C., Yeh Y. C., Wang L. C., Ting C. T., Lee W. L., Lee H. W., Wang K. Y., Wu A., Su C. S., Liu T. J., Propofol ameliorates doxorubicin-induced oxidative stress and cellular apoptosis in rat cardiomyocytes. Toxicology and Applied Pharmacology 2011 257 3 437 448 2-s2.0-84855734341 10.1016/j.taap.2011. 10.001
79. van Dalen E. C., Caron H. N., Dickinson H. O., Kremer L. C., Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database of Systematic Reviews 2008 2 CD003917 2-s2.0-44949174094
80. Kwok J. C., Richardson D. R., The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Report 2000 5 6 317 324 2-s2.0-0034523687 10.1179/135100000101535898 (Pubitemid 32040825)
81. Cvetković R. S., Scott L. J., Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005 65 7 1005 1024 2-s2.0-18744377282 10.2165/00003495-200565070-00008 (Pubitemid 40667518)
82. Broder S., The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Research 2010 85 1 1 18 2-s2.0-73549103358 10.1016/j.antiviral.2009.10.002
83. Dalakas M. C., Illa I., Pezeshkpour G. H., Laukaitis J. P., Cohen B., Griffin J. L., Mitochondrial myopathy caused by long-term zidovudine therapy. The New England Journal of Medicine 1990 322 16 1098 1105 2-s2.0-0025274663 (Pubitemid 20149526)
84. Benbrik E., Chariot P., Bonavaud S., Ammi-Saïd M., Frisdal E., Rey C., Gherardi R., Barlovatz-Meimon G., Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. Journal of the Neurological Sciences 1997 149 1 19 25 2-s2.0-0031003145 10.1016/S0022-510X(97)05376-8 (Pubitemid 27196376)
85. Amatore C., Arbault S., Jaouen G., Koh A. C. W., Leong W. K., Top S., Valleron M. A., Woo C. H., Pro-oxidant properties of AZT and other thymidine analogues in macrophages: implication of the azido moiety in oxidative stress. ChemMedChem 2010 5 2 296 301 2-s2.0-75749123458 10.1002/cmdc.200900464
86. Kline E. R., Bassit L., Hernandez-Santiago B. I., Detorio M. A., Liang B., Kleinhenz D. J., Walp E. R., Dikalov S., Jones D. P., Schinazi R. F., Sutliff R. L., Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovascular Toxicology 2009 9 1 1 12 2-s2.0-66849115212 10.1007/s12012-008-9029-8
87. Sprauten M., Darrah T. H., Peterson D. R., Campbell M. E., Hannigan R. E., Cvancarova M., Beard C., Haugnes H. S., Fosså S. D., Oldenburg J., Travis L. B., Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. Journal of Clinical Oncology 2012 30 3 300 307 2-s2.0-84856015361 10.1200/JCO.2011.37.4025
88. Cristofori P., Zanetti E., Fregona D., Piaia A., Trevisan A., Renal proximal tubule segment-specific nephrotoxicity: an overview on biomarkers and histopathology. Toxicologic Pathology 2007 35 2 270 275 2-s2.0-33847772869 10.1080/01926230601187430 (Pubitemid 46393079)
89. Burger H., Zoumaro-Djayoon A., Boersma A. W. M., Helleman J., Berns E. M. J. J., Mathijssen R. H. J., Loos W. J., Wiemer E. A. C., Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). British Journal of Pharmacology 2010 159 4 898 908 2-s2.0-77249130793 10.1111/j.1476-5381.2009.00569.x
90. Filipski K. K., Mathijssen R. H., Mikkelsen T. S., Schinkel A. H., Sparreboom A., Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clinical Pharmacology and Therapeutics 2009 86 4 396 402 2-s2.0-70349440952 10.1038/clpt.2009.139
91. Masuda H., Tanaka T., Takahama U., Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochemical and Biophysical Research Communications 1994 203 2 1175 1180 2-s2.0-0027965261 10.1006/bbrc.1994.2306 (Pubitemid 24304953)
92. 2 production in cisplatin-induced nephrotoxicity. Biochemical and Biophysical Research Communications 1998 242 2 310 312 2-s2.0-0032515236 10.1006/bbrc.1997.7962 (Pubitemid 28412424)
93. Chirino Y. I., Pedraza-Chaverri J., Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Experimental and Toxicologic Pathology 2009 61 3 223 242 2-s2.0-67349112401 10.1016/j.etp.2008.09.003
94. Santos N. A. G., Catão C. S., Martins N. M., Curti C., Bianchi M. L. P., Santos A. C., Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Archives of Toxicology 2007 81 7 495 504 2-s2.0-34347352096 10.1007/s00204-006-0173-2 (Pubitemid 47012464)
95. Van Ruijven M. W. M., De Groot J. C. M. J., Klis S. F. L., Smoorenburg G. F., The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hearing Research 2005 205 1-2 241 248 2-s2.0-20444446307 10.1016/j.heares.2005.03.023 (Pubitemid 40813286)
96. Meech R. P., Campbell K. C. M., Hughes L. P., Rybak L. P., A semiquantitative analysis of the effects of cisplatin on the rat stria vascularis. Hearing Research 1998 124 1-2 44 59 2-s2.0-0031760577 10.1016/S0378-5955(98)00116-6 (Pubitemid 28483064)
97. Kim H. J., Lee J. H., Kim S. J., Oh G. S., Moon H. D., Kwon K. B., Park C., Park B. H., Lee H. K., Chung S. Y., Park R., So H. S., Roles of NADPH oxidases in cisplatin-induced reactive oxygen species generation and ototoxicity. Journal of Neuroscience 2010 30 11 3933 3946 2-s2.0-77949699981 10.1523/JNEUROSCI.6054-09.2010
98. Ravi R., Somani S. M., Rybak L. P., Mechanism of cisplatin ototoxicity: antioxidant system. Pharmacology and Toxicology 1995 76 6 386 394 2-s2.0-0029012886
99. van den Berg J. H., Beijnen J. H., Balm A. J. M., Schellens J. H. M., Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treatment Reviews 2006 32 5 390 397 2-s2.0-33746007179 10.1016/j.ctrv.2006.04. 011 (Pubitemid 44063878)
100. Planting A. S. T., Catimel G., De Mulder P. H. M., De Graeff A., Höppener F., Verweij J., Oster W., Vermorken J. B., Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Annals of Oncology 1999 10 6 693 700 2-s2.0-0032775070 10.1023/A:1008353505916 (Pubitemid 29342375)
101. Ekborn A., Hansson J., Ehrsson H., Eksborg S., Wallin I., Wagenius G., Laurell G., High-dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 2004 114 9 1660 1667 2-s2.0-4644262696 10.1097/00005537-200409000-00030 (Pubitemid 39278890)
102. Onoue S., Kawamura K., Igarashi N., Zhou Y., Fujikawa M., Yamada H., Tsuda Y., Seto Y., Yamada S., Reactive oxygen species assay-based risk assessment of drug-induced phototoxicity: classification criteria and application to drug candidates. Journal of Pharmaceutical and Biomedical Analysis 2008 47 4-5 967 972 2-s2.0-46549087839 10.1016/j.jpba.2008.03.026
103. Bokemeyer C., Berger C. C., Hartmann J. T., Kollmannsberger C., Schmoll H. J., Kuczyk M. A., Kanz L., Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British Journal of Cancer 1998 77 8 1355 1362 2-s2.0-0031885884 (Pubitemid 28140629)
104. Oldenburg J., Kraggerud S. M., Cvancarova M., Lothe R. A., Fossa S. D., Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. Journal of Clinical Oncology 2007 25 6 708 714 2-s2.0-33947590154 10.1200/JCO.2006.08.9599 (Pubitemid 350002927)
105. Mukherjea D., Rybak L. P., Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics 2011 12 7 1039 1050 2-s2.0-79960807006 10.2217/pgs.11.48
106. Bray J., Sludden J., Griffin M. J., Cole M., Verrill M., Jamieson D., Boddy A. V., Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British Journal of Cancer 2010 102 6 1003 1009 2-s2.0-77949539805 10.1038/sj.bjc.6605587
107. Glynn S. A., Boersma B. J., Howe T. M., Edvardsen H., Geisler S. B., Goodman J. E., Ridnour L. A., Lonning P. E., Borresen-Dale A. L., Naume B., Kristensen V. N., Chanock S. J., Wink D. A., Ambs S., A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research 2009 15 12 4165 4173 2-s2.0-67449138836 10.1158/1078-0432.CCR- 09-0119
108. Jamieson D., Boddy A. V., Pharmacogenetics of genes across the doxorubicin pathway. Expert Opinion on Drug Metabolism and Toxicology 2011 7 10 1201 1210 2-s2.0-80052980622 10.1517/17425255.2011.610180
109. Singh K. K., Shukla P. C., Quan A., Desjardins J.-F., Lovren F., Pan Y., Garg V., Gosal S., Garg A., Szmitko P. E., Schneider M. D., Parker T. G., Stanford W. L., Leong-Poi H., Teoh H., Al-Omran M., Verma S., BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. The Journal of Biological Chemistry 2012 287 9 6604 6614 2-s2.0-84857466300 10.1074/jbc.M111.292664
110. Bensaad K., Vousden K. H., Savior and slayer: the two faces of p53. Nature Medicine 2005 11 12 1278 1279 2-s2.0-28644448262 10.1038/nm1205-1278 (Pubitemid 41752901)
111. Sawyer D. B., Peng X., Chen B., Pentassuglia L., Lim C. C., Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Progress in Cardiovascular Diseases 2010 53 2 105 113 2-s2.0-77955906955 10.1016/j.pcad.2010.06.007
112. Raschi E., Vasina V., Ursino M. G., Boriani G., Martoni A., de Ponti F., Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacology and Therapeutics 2010 125 2 196 218 2-s2.0-77249101995 10.1016/j.pharmthera.2009.10.002
113. Kohler J. J., Cucoranu I., Fields E., Green E., He S., Hoying A., Russ R., Abuin A., Johnson D., Hosseini S. H., Raper C. M., Lewis W., Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy. Laboratory Investigation 2009 89 7 782 790 2-s2.0-67649861056 10.1038/labinvest.2009.39
114. Hickey E. J., Raje R. R., Reid V. E., Gross S. M., Ray S. D., Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radical Biology and Medicine 2001 31 2 139 152 2-s2.0-0035879827 10.1016/S0891-5849(01)00560-3 (Pubitemid 32607581)
115. Boelsterli U. A., Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicology and Applied Pharmacology 2003 192 3 307 322 2-s2.0-0142219774 10.1016/S0041-008X(03)00368-5 (Pubitemid 37311346)
116. Stirnimann G., Kessebohm K., Lauterburg B., Liver injury caused by drugs: an update. Swiss Medical Weekly 2010 140 18 24 2-s2.0-78650604361 10.4414/smw.2010.13080
117. Daugaard G., Abildgaard U., Cisplatin nephrotoxicity. A review. Cancer Chemotherapy and Pharmacology 1989 25 1 1 9 2-s2.0-0024350380 10.1007/BF00694330 (Pubitemid 20000790)